Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025)
Sutro Biopharma (STRO) posted Change in Accured Expenses of -$79000.0 for Q4 2025, down 101.66% sequentially from $4.8 million in Q3 2025, and up 89.38% YoY from -$41714.7 in Q4 2024.
Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025) Analysis & Trends
Sutro Biopharma has reported Change in Accured Expenses for 9 years, with the latest figure at -$79000.0 in Q4 2025.
- Quarterly Change in Accured Expenses rose 89.38% year-over-year to -$79000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 148.3% YoY) and the FY2025 annual result came in at $3.6 million, up 148.3% from the prior year.
- Change in Accured Expenses eased to -$79000.0 in Q4 2025 per STRO's latest filing, from $4.8 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $20.7 million in Q4 2023 and troughed at -$6.7 million in Q2 2025.
- A 5-year average of $1.7 million and a median of $58000.0 in 2021 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1249.74% in 2022, down 2150.56% in 2022.
- Over 5 years, Change in Accured Expenses stood at $5.2 million in 2021, then jumped by 45.1% to $7.6 million in 2022, then jumped by 172.68% to $20.7 million in 2023, then sank by 103.59% to -$744000.0 in 2024, then soared by 89.38% to -$79000.0 in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$79000.0, $4.8 million, and -$6.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79,000.00 |
| Dec 31, 2025 | -79,000.00 |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | -6.69 Mn |
| Jun 30, 2025 | -6.69 Mn |
| Mar 31, 2025 | 5.55 Mn |
| Mar 31, 2025 | 5.55 Mn |
| Dec 31, 2024 | -744,000.00 |
| Dec 31, 2024 | -744,000.00 |
| Sep 30, 2024 | -1.86 Mn |
| Sep 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | -3.98 Mn |
| Jun 30, 2024 | -3.98 Mn |
| Mar 31, 2024 | -765,000.00 |
| Mar 31, 2024 | -765,000.00 |
| Dec 31, 2023 | 20.72 Mn |
| Dec 31, 2023 | 20.72 Mn |
| Sep 30, 2023 | 8.21 Mn |
| Sep 30, 2023 | 8.21 Mn |